Home The Word Brain | My Amedeo FAQ Privacy About | ||||||||||
The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al. |
Malignant Lymphoma |
Free Subscription
1 Am J Hematol |
Retrieve available abstracts of this week’s articles:
HTML format |
Single Articles |
AMEDEO Malignant Lymphoma is free of charge.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in
relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol. 2024 May 3. doi: 10.1002/ajh.27341.
PubMed
Abstract available
Motive and Opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC
and BCL2 rearrangements-an LLMPP study.
Blood. 2024 May 3:blood.2024024251. doi: 10.1182/blood.2024024251.
PubMed
Abstract available
Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large
B-cell lymphoma therapy: A Meta-analysis.
Blood. 2024 May 2:blood.2023023419. doi: 10.1182/blood.2023023419.
PubMed
Abstract available
T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell
ADCC.
Blood. 2024;143:1816-1824.
PubMed
Abstract available
Managing common toxicities associated with checkpoint inhibitor and chemotherapy
combinations for untreated classic Hodgkin lymphoma.
Br J Haematol. 2024 May 2. doi: 10.1111/bjh.19478.
PubMed
Abstract available
Pulmonary diseases in patients with classical Hodgkin lymphoma relative to a
matched background population: A Danish national cohort study.
Br J Haematol. 2024 Apr 29. doi: 10.1111/bjh.19475.
PubMed
Abstract available
Nivolumab combined with brentuximab vedotin with or without mediastinal
radiotherapy for relapsed/refractory primary mediastinal large B-cell lymphoma.
Haematologica. 2024 May 2. doi: 10.3324/haematol.2023.284689.
PubMed
Abstract available
Real-world patterns and sequences of targeted therapy use in chronic lymphocytic
leukemia and small lymphocytic lymphoma in the United States: a longitudinal
study.
Leuk Lymphoma. 2024 May 2:1-11. doi: 10.1080/10428194.2024.2331631.
PubMed
Abstract available
The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone
in relapsed or refractory mantle cell lymphoma-a randomized, open-label phase III
trial of the European mantle cell lymphoma network.
Leukemia. 2024 Apr 27. doi: 10.1038/s41375-024-02254.
PubMed
Abstract available
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle
cell lymphoma.
PLoS One. 2024;19:e0289902.
PubMed
Abstract available
Thank you for your interest in scientific medicine.